Oxford Biomedica to acquire ABL Europe from Institut Mérieux, consolidating as global pure-play CDMO

 

• Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe
• The transaction
  • Provides Oxford Biomedica with multi viral vector CDMO capabilities – to be made available across the Company’s six manufacturing sites in EU, US and UK
  • Expands Oxford Biomedica’s capacity in process and analytical development and early-stage manufacturing to better address client needs
  • Provides new facilities in France to enhance service for clients adding process development and manufacturing capacity in the EU
  • Reinforces Oxford Biomedica’s position as a world leading cell and gene therapy CDMO
• Institut Mérieux intends to increase current ownership in Oxford Biomedica from 3.3 per cent to approximately 10.0 per cent of the enlarged issued share capital by the end of Q3 2024
   

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into a sale and purchase agreement (the “Agreement”) with TSGH SAS, a subsidiary of Institut Mérieux SA ("Institut Mérieux"), for the acquisition of ABL Europe SAS (“ABL Europe”) (the "Transaction"). This follows the announcement on 20 September 2023, of exclusive negotiations in relation to the proposed acquisition by Oxford Biomedica of ABL Europe, a pure-play European CDMO with specialised expertise in the development and manufacturing of solutions for biotechs and biopharma including viruses for gene therapy, oncolytic viruses and vaccine candidates, in exchange for Oxford Biomedica ordinary shares.

The acquisition of ABL Europe will consolidate Oxford Biomedica's operations into a global pure-play CDMO in the cell and gene therapy space. It will broaden the Company's international presence by establishing a footprint within the European Union through facilities located in Lyon and Strasbourg, France. In addition, the acquisition will increase Oxford Biomedica’s capacity in process and analytical development and early-stage manufacturing and address increased client demand for process development.

https://www.biospace.com/article/releases/oxford-biomedica-signs-agreement-to-acquire-abl-europe-from-institut-merieux-consolidating-position-as-a-global-pure-play-cdmo/